



## Press release

### **Reminder: Invitation to Capital Markets Day 2012**

**Uppsala, Sweden, April 26, 2012 – We have the pleasure of inviting analysts, investors and media to Orexo's Capital Markets Day 2012 to be held in Stockholm on May 3, 2012.**

**Date:** Thursday May 3, 2012  
**Time:** 2 p.m. to 5 p.m.  
**Venue:** Sveavägen 20, 9th floor, Stockholm. (Please note the change to Stockholm)  
**RSVP:** registration ASAP via email to [info@orexo.com](mailto:info@orexo.com)

### **Agenda and speakers**

Orexo's new management will present the strategy, a financial review, a business update on Abstral and other launched products together with status and ambitions with the proprietary development programs (see agenda on the next page). The following speakers from the company will give presentations:

- Anders Lundström (President and CEO)
- Carl-Johan Blomberg (Chief Financial Officer)
- Peter Edman (Chief Scientific Officer)
- Åsa Holmgren (Head of Regulatory Affairs)
- Nikolaj Sørensen (Chief Commercial Officer)

In addition to the management team **Jennifer Filbey, PhD**, President of New Perspectives Inc., will provide a US perspective on the opioid dependence market for OX219 and **Dr. Mark Watling**, Senior Partner of TranScrip Partners LLP will provide his perspective on the relevant market for OX51.

The Capital Markets Day will be held in English and afterwards all presentations will be available on Orexo's website [www.orexo.com](http://www.orexo.com). For questions, please contact Beata Augenblick, phone: +46 70 622 59 93.

I look forward to meet you on May 3,

Anders Lundström  
President and CEO

### **About Orexo**

Orexo develops and markets pharmaceuticals based on proprietary drug delivery technologies applied to well-known substances. The company's largest product is Abstral, a treatment of breakthrough cancer pain. Orexo's shares are listed on the Stockholm Stock Exchange and Danish Novo A/S and Swedish HealthCap are the largest shareholders. More information can be found at [www.orexo.com](http://www.orexo.com)



## Agenda

**2.00 - 3.40 pm**

- **Orexo's business model**  
Anders Lundström, President & CEO
- **Proven track record: Diabact®, Heliprobe®, Abstral®, Edluar™**  
Anders Lundström, President & CEO
- **An exciting pipeline**  
**Presentation of Orexo's key project:**  
**OX27 – breakthrough cancer pain**  
**OX51 – procedure induced pain**  
**OX219 – opioid dependence**  
Peter Edman, CSO
- Procedure induced pain – a significant opportunity for OX51**  
Dr. Mark Watling, Senior Partner, TranScrip Partners
- Opportunities and advantages of 505(b)(2)**  
**– a smart registration path in the US**  
Åsa Holmgren, Head Regulatory Affairs
- The US market for treatment of opioid dependence**  
Jennifer A. Filbey, Ph.D, CEO for New Perspectives Inc

*3.40 - 4.00 pm*

*Coffee break*

**4.00 - 5.00 pm**

- **Commercializing in the US**  
Nikolaj Sørensen, CCO
- **A strong financial position**  
Carl Johan Blomberg, CFO
- **The years ahead**  
Anders Lundström, President & CEO
- **Q&A session**